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Editorial on the Research Topic
Cerebrovascular and Neurodegenerative Diseases - New Insights into Molecular Cell Biology
and Therapeutic Targets
There is a significant gap in our understanding of the molecular and cellular biology of
cerebrovascular and neurodegenerative diseases to identify new therapeutic targets and develop
diagnostic tools to better understand the disease progression and treatment. The cellular and
molecular events linking cerebrovascular pathology and neurodegeneration are also not fully
understood. The research articles and review papers published in this topic aim at a multifaceted
approach to evaluating recent progress in our understanding some of the underlying molecular
mechanisms of disease process and potential therapeutics targeting these diseases. Here we
summarize the contributing articles to our topic conveying the aim of the pertaining research.
The articles in this Research Topic highlight the challenges inspiring future research to address
some of the questions and to exploit new opportunities for development of novel therapeutics for
cerebrovascular and neurodegenerative diseases.
Smith-Dijak et al. studied the effects of pridopidine, a drug that enhances brain derived
neurotrophic factor (BDNF) signaling through stimulation of the sigma-1 receptor (S1R) and S1R
agonist, in cortical neurons obtained from a mouse model of Huntington disease (HD). Several
pathways implicated in synaptic functions are dysregulated in HD, including BDNF and calcium
signaling. The data provide evidence for restoration of synaptic plasticity that maintain the stability
of neuronal and synaptic function required for new learning and cognitive function. The results
suggest a potential new direction for developing therapy to mitigate cognitive deficits in HD and
may provide new avenues for neuroinflammation-related disorders treatment.
Agouni et al. provided a comprehensive analysis of circulating extracellular vesicles (EVs) from
vascular wall, blood, and immune cells in transient ischemic attacks (TIA) and acute ischemic
stroke (AIS) patients from Southeast Asia and the Middle East. This study showed that EVs of
various origins, especially those associated with endothelial cell injury and platelet activation,
are increased in TIA and AIS patients. The levels of EV continue to be high for up to 30-days
post-attacks indicating a sustained cellular activation, which may be associated with an increased
risk of recurrence of acute events in this population.
D’Angelo et al. carried out a review on antiphospholipid syndrome (APS) and multiple
sclerosis (MS). APS and MS are both considered as anti-lipid autoimmune diseases with specific
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pathophysiological mechanisms and events. Isolated neurological
APS represents a significant diagnostic challenge, as
epidemiological, clinical, and neuroimaging features may
overlap with those of MS. The review draws attention to the
clinical relevance of diagnosing isolated neurological APS and
suggests that prompt and accurate diagnosis and treatment of
APS with anti-aggregant and anticoagulant could be vital to
prevent or reduce APS-related morbidity and mortality.
Wei et al. examined the cellular mechanisms mediating the
neuroprotective effects of Homer1a, a short form of a scaffold
protein, which is upregulated in rat cortical neurones following
oxygen and glucose deprivation (OGD) mimicking ischemia-
reperfusion (I/R) injury. The results showed that overexpression
of Homer1a reduced OGD-induced lactate dehydrogenase
(LDH) release, cell death, and mitochondrial dysfunctions in
cultured cortical neurons. Homer1a also protects against OGD-
induced injury by preserving mitochondrial function through
inhibiting the protein kinase R-like endoplasmic reticulum
kinase (PERK) pathway. In addition, mitochondrial protection
of Homer1a was blocked by the ER stress activator tunicamycin
(TM) suggesting that Homer1a may be a promising target of
protecting neurons from cerebral injury.
Yang et al. examined the effect of cyclooxygenase
(COX2)/prostaglandin D2 (PGD2)-related autophagy on
brain injury in diabetic rats suggesting that the COX2-PGD2
pathway is a potential therapeutic target for diabetic brain injury.
Xu et al., reported that low-moderate ethanol consumption
may prevent ischemic stroke and reduce brain cerebral
ischemia/reperfusion injury (I/R) by suppressing inflammation,
whereas heavy alcohol consumption may induce ischemic stroke
and worsen brain I/R injury by aggravating inflammation.
He et al. found that smilagenin, a steroidal sapogenin from
traditional Chinese medicinal herbs, can have neuroprotective
effect on dopaminergic neurons in a chronic mouse model of
Parkinson’s disease (PD) suggesting that this drug could prevent
the impairment of dopaminergic neurons in PD.
Zhang et al. demonstrated that Naringenin (NAR), a
grapefruit flavonoid promoted microglia M1/M2 polarization,
thus conferring anti-neuroinflammatory effects via the inhibition
of mitogen-activated protein kinase (MAPK) signaling
activation. These findings provide new alternative avenues
for neuroinflammation-related disorders treatment.
Hao et al. showed that heterozygous loss of activin receptor-
like kinase 1 (Alk1) can lead to hereditary hemorrhagic
telangiectasia, which is a vascular disease characterized by direct
connections between arteries and veins leading to arteriovenous
malformations (AVMs). The results of the study suggest that
Alk1 induces the formation of sporadic human cerebral AVMs
through affecting migration and proliferation of endothelial cells
combined with vascular endothelial growth factor A.
Li et al. developed a flow cytometry protocol to identify
microglia and monocyte-derived macrophages from mouse
intracerebral hemorrhagic (ICH) stroke model induced by
collagenase or blood injection. The authors also combined
magnetic-activated cell separation system that allows eight
tissue samples to be assessed together. This protocol represents
a very important tool for biological functions of microglial
and monocyte-derived macrophage in ICH stroke and related
brain diseases.
Jin et al., showed that glucose-regulated protein (GRP78) a
chaperone protein located in the endoplasmic reticulum (ER)
is involved in the neuroglial response to neurotoxic insult in
rats induced by mitochondrial toxin 3-nitropropionic acid (3-
NP), which selectively damages striatal neurons. These data
provide novel insights into the phenotypic and functional
heterogeneity of GRP78-positive cells within the lesion core
and the involvement of GRP78 in the activation/recruitment
of activated microglia/macrophages and blood-brain-barrier
impairment in response neurotoxic insult.
Song et al. reported that the knock down of myosin
light chain kinase, a key enzyme in smooth muscle cell
contraction, in human brain smooth muscle cells (SMCs)
caused effects similar to those observed in cultured SMCs
from intracranial aneurysm patients. These results indicate
that myosin light chain kinase plays an important role in
maintaining smooth muscle contractility, cell survival and
inflammation tolerance and is crucial to the normal function of
intracranial arteries.
Hoyk et al. showed elevated serum triglyceride levels, changes
in functional and morphological gene expressions and blood
brain barrier dysfunction in transgenic mice overexpressing
the human APOB-100 protein, a mouse model of human
atherosclerosis suggesting that these transgenic mice could be a
useful model to study the link between cerebrovascular pathology
and neurodegeneration.
Yu et al. reported that injection of hydroxysafflor yellow A
(HSYA), a major active chemical component of the safflower
via carotid artery improves cognitive impairment and synaptic
plasticity in a rat model of stroke induced by middle cerebral
artery occlusion.
Chen et al. showed that Gap19, a selective Connexin 43 (Cx43)
-hemi -channel inhibitor, produces neuroprotective effects in
cerebral ischemia/reperfusion injury induced by middle cerebral
artery occlusion in mice via suppression of Cx43 and Toll-like
receptor 4 (TLR4) mediated signaling pathways.
Chang et al. developed a new in vitro cerebral micro-
bleed model to study the interactions between brain endothelial
cells and red blood cells exposed to oxidative stress. Their
findings demonstrate that erythrophagocytosis mediated by
the brain endothelial monolayer and the passage of iron-rich
hemoglobin and RBC, may be involved in the development of
cerebral microbleeds that are not dependent on disruption of
the microvasculature.
Faustino-Mendes et al. reviewed the current experimental
models of immature ischemic brain and highlighted the need for
new multifactorial experimental models to attain more efficient
therapies to treat this complex vascular condition and related
long-term conditions.
Chen et al. showed that the compound 22a, a promising
neuroprotective compound derived from tetramethylpyrazine
and widely used as active ingredient of traditional Chinese
medicine, effectively prevented glutamate-induced excitotoxicity
in cerebellar granule cells (CGNs) via involvement of the
PI3K/Akt and PGC1α/Nrf2 pathways suggesting that this
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compound might be useful in preventing neuronal death from
ischemic stroke.
Du et al. tested a hypothesis that chemokine interleukin
(IL) eight released by astrocytes and C-X-C motif chemokine
receptor 1 (CXCR1) in neurons are involved in neuronal
apoptosis induced by methamphetamine (METH), a widely
abused illicit drug, which can cause dopaminergic neuron
apoptosis and astrocyte-related neuroinflammation. The results
suggest that CXCR1may be a potential target for METH-induced
neurotoxicity therapy.
Lu et al., aimed to explore the protective effects of rosuvastatin,
a 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitor, against haemorrhagic transformation (HT)
after recombinant tissue plasminogen activator (rt-PA) treatment
in a mouse model of experimental stroke. The beneficial effects
are related to inhibition of the inflammation-related nuclear
factor kappa B (NF-κB) and mitogen-activated protein kinase
(MAPK) pathways.
Wang et al. showed that mild ER stress (“preconditioning”)
induced by tunicamycin (TM), can alleviate LPS-induced
astrocytic activation and BBB disruption. Their findings
provide a better understanding for the regulatory role of
ER stress in neuroinflammation and indicate that mild ER
stress might have therapeutic value for the treatment of
neurodegenerative diseases.
Yang et al., found that adapentpronitrile, a new adamantane-
based dipeptidyl peptidase-IV (DPP-IV) inhibitor significantly
ameliorated neuronal injury and decreased amyloid precursor
protein (APP) and amyloid beta (Aβ) expression in the
hippocampus and cortex of rat model of diabetes fed with high
fat diet. These authors showed that adapentpronitrile protected
against diabetic neuronal injury by inhibiting mitochondrial
oxidative stress and the apoptotic pathway.
Jang et al. reported intrastriatal injection of adeno-associated
viral vector serotype DJ containing N171-82Qmutant huntingtin
(HTT) gene to juvenile mice produced Huntington’s disease
(HD)-like symptoms including mutant HTT aggregation,
neurodegeneration, and Neuroinflammation. The authors
suggested that this model will a useful tool to better understand
neuropathological mechanisms of HD and develop new
therapeutics for this disease.
Hao et al. established a stable method for the isolation of
endothelial cells (ECs) from human cerebral arteriovenous
malformation tissues, which play an important role in
the manifestation and development of cerebral vascular
malformation as well as haemorrhagic stroke and
thrombogenesis. The protocol can also be adapted for other
vascular diseases.
He et al. demonstrated that rosuvastatin treatment
significantly increased neurite outgrowth in cortical neurons
after oxygen-glucose deprivation (OGD)-induced damage,
reduced the generation of reactive oxygen species, protected
mitochondrial function and elevated the ATP levels via Notch1
pathway. These findings highlight Notch1 signaling as important
player and novel therapeutic target in promoting brain plasticity.
In summary, the present Research Topic encompassed
several cutting-edge techniques and models for investigating
the cellular and molecular mechanisms of cerebrovascular
dysfunction and neurodegeneration. Together, they provide a
framework for understanding the way some of the diseases
progress and potential pathways for therapeutic interventions.
We acknowledged that collection of articles in a single topic
cannot deal with this extremely vast subject characterized
by complex conditions such as cerebrovascular dysfunction
and neurodegeneration. The topics addressed, however, help
developing clear ideas, not only in terms of recent studies
but also the unmet needs for future research in these
areas. We trust that the papers assembled in this Research
Topic will prove useful in encouraging and stimulating
future progress in research related to cerebrovascular and
neurodegenerative diseases.
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